乳腺癌MRI对侧实质强化与长期生存相关:SELECT研究结果
这项多中心回顾性队列纳入1432例单侧ER阳性HER2阴性乳腺癌患者,评估MRI对侧实质强化(CPE)与长期生存的关系。
要点
- CPE与总生存独立相关,高CPE组10年总生存率略低。
- CPE与无复发生存及远处无复发生存无显著关联。
- 内分泌治疗疗效与CPE的关联因数据限制无法可靠评估。
核心结论
- 高对侧实质强化与ER阳性HER2阴性乳腺癌患者总生存轻度下降相关,但与无复发生存和远处无复发生存无关。
诊断标准与关键数值
- 按CPE三分位分层,10年总生存率分别为三分位1组88.5%(95%CI:88.1,89.1)、三分位2组85.8%(95%CI:85.2,86.3)、三分位3组85.9%(95%CI:85.4,86.4)。
临床应用与阅片要点
- 乳腺MRI报告可关注对侧实质强化程度,高CPE或提示总生存轻度下降,但不足以单独改变治疗决策。
局限性
- 回顾性设计,内分泌治疗疗效与CPE的关联因无法准确评估内分泌治疗对生存的影响而未能可靠估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Several single-center studies found that high contralateral parenchymal enhancement (CPE) at breast MRI was associated with improved long-term survival in patients with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Due to varying sample sizes, population characteristics, and follow-up times, consensus of the association is currently lacking. Purpose To confirm whether CPE is associated with long-term survival in a large multicenter retrospective cohort, and to investigate if CPE is associated with endocrine therapy effectiveness. Materials and Methods This multicenter observational cohort included women with unilateral ER-positive HER2-negative breast cancer (tumor size ≤50 mm and ≤three positive lymph nodes) who underwent MRI from January 2005 to December 2010. Overall survival (OS), recurrence-free survival (RFS), and distant RFS (DRFS) were assessed. Kaplan-Meier analysis was performed to investigate differences in absolute risk after 10 years, stratified according to CPE tertile. Multivariable Cox proportional hazards regression analysis was performed to investigate whether CPE was associated with prognosis and endocrine therapy effectiveness. Results Overall, 1432 women (median age, 54 years [IQR, 47-63 years]) were included from 10 centers. Differences in absolute OS after 10 years were stratified according to CPE tertile as follows: 88.5% (95% CI: 88.1, 89.1) in tertile 1, 85.8% (95% CI: 85.2, 86.3) in tertile 2, and 85.9% (95% CI: 85.4, 86.4) in tertile 3. CPE was independently associated with OS, with a hazard ratio (HR) of 1.17 (95% CI: 1.0, 1.36; P = .047), but was not associated with RFS (HR, 1.11; P = .16) or DRFS (HR, 1.11; P = .19). The effect of endocrine therapy on survival could not be accurately assessed; therefore, the association between endocrine therapy efficacy and CPE could not reliably be estimated. Conclusion High contralateral parenchymal enhancement was associated with a marginally decreased overall survival in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer, but was not associated with recurrence-free survival (RFS) or distant RFS. Published under a CC BY 4.0 license. Supplemental material is available for this article. See also the editorial by Honda and Iima in this issue.
引用
- Ragusi, van der Velden, Meeuwis, et al. Long-term Survival in Breast Cancer Patients Is Associated with Contralateral Parenchymal Enhancement at MRI: Outcomes of the SELECT Study. Radiology. 2023. PMID: 36975820. doi:10.1148/radiol.221922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。